Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)

被引：0
|
作者：
Flinn, Ian W.
Gribben, John G.
Dyer, Martin J. S.
Wierda, William G.
Maris, Michael B.
Furman, Richard R.
Hillmen, Peter
Jones, Jeffrey
Iyer, Swami P.
Jones, Surai
Jiang, Yanwen
Pignataro, Daniela Soriano
Humphrey, Kathryn
Mobasher, Mehrdad
Kipps, Thomas J.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
430
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Safety of Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Results from the Primary Analysis of the Phase 3b GREEN Study
    Stilgenbauer, Stephan
    Aktan, Melih
    Coll, Christelle M. Ferra
    Dartigeas, Caroline
    Kisro, Jens
    Montillo, Marco
    Raposo, Joao
    Merot, Jean-Louis
    Robson, Susan
    Gresko, Ekaterina
    Bosch, Francesc
    Foa, Robin
    Leblond, Veronique
    BLOOD, 2017, 130
  • [42] Fixed-Duration Venetoclax-Obinutuzumab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: Follow-Up of Efficacy and Safety Results From the Multicenter, Open-Label, Randomized, Phase III CLL14 Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 11 - 11
  • [43] The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study
    Martinez-Lopez, Joaquin
    Mustjoki, Satu
    Porkka, Kimmo
    Klisovic, Rebecca B.
    Wolf, Dominik
    Busque, Lambert
    Hernandez-Boluda, Juan Carlos
    Swanink, Rene
    Martin Regueira, Patricia
    Lipton, Jeffrey H.
    LEUKEMIA & LYMPHOMA, 2021, 62 (08) : 2040 - 2043
  • [44] Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial
    Divya Samineni
    Leonid Gibiansky
    Bei Wang
    Shweta Vadhavkar
    Richa Rajwanshi
    Maneesh Tandon
    Arijit Sinha
    Othman Al-Sawaf
    Kirsten Fischer
    Michael Hallek
    Ahmed Hamed Salem
    Chunze Li
    Dale Miles
    Advances in Therapy, 2022, 39 : 3635 - 3653
  • [45] Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study
    Roboz, Gail J.
    Pabst, Thomas
    Aribi, Ahmed
    Brandwein, Joseph M.
    Dohner, Hartmut
    Fiedler, Walter
    Gandini, Domenica
    Geddes, Michelle
    Hou, Jing-Zhou
    Howes, Angela J.
    Hultberg, Anna
    Huselton, Eric
    Jacobs, Julie
    Kane, Colleen
    Lech-Maranda, Ewa
    Louwers, Marieke
    Nottage, Kerri
    Platzbecker, Uwe
    Rampal, Raajit
    Salman, Mariya
    Shah, Priya
    Stevens, Don
    Stuart, Monic
    Subklewe, Marion
    Sumbul, Anne
    Wang, Eunice S.
    Wierzbowska, Agnieszka
    Yao, Bin
    Yee, Karen
    Kantarjian, Hagop
    Borthakur, Gautam
    BLOOD, 2021, 138
  • [46] Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia
    Soumerai, Jacob D.
    Davids, Matthew S.
    Werner, Lillian
    Fisher, David C.
    Armand, Philippe
    Amrein, Philip C.
    Neuberg, Donna
    Hochberg, Ephraim P.
    Brown, Jennifer R.
    Abramson, Jeremy S.
    LEUKEMIA & LYMPHOMA, 2019, 60 (12) : 2931 - 2938
  • [47] Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study
    Stilgenbauer, Stephan
    Bosch, Francesc
    Ilhan, Osman
    Kisro, Jens
    Mahe, Beatrice
    Mikuskova, Eva
    Osmanov, Dzhelil
    Reda, Gianluigi
    Robinson, Sue
    Tausch, Eugen
    Turgut, Mehmet
    Wojtowicz, Marcin
    Boettcher, Sebastian
    Perretti, Thomas
    Trask, Peter
    Van Hoef, Marlies
    Leblond, Veronique
    Foa, Robin
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (02) : 325 - 338
  • [48] Fixed-Duration Pirtobrutinib Combined with Venetoclax ± Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results, Including MRD Data, from the BRUIN Phase 1b Study
    Roeker, Lindsey E.
    Woyach, Jennifer A.
    Cheah, Chan Y.
    Coombs, Catherine C.
    Shah, Nirav N.
    Wierda, William G.
    Patel, Manish
    Tsai, Donald E.
    Nair, Binoj
    Wang, Chunxiao
    Zhao, Xiang
    Marella, Narasimha
    Ho, Caleb
    McNeely, Samuel
    Brown, Jennifer R.
    BLOOD, 2023, 142
  • [49] Bendamustine and Rituximab in combination with Lenalidomide in patients with relapsed or refractory and in patients with previously untreated chronic lymphocytic leukemia: A multicenter phase I/II safety and efficacy trial of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG)
    Pflug, N.
    Maurer, C.
    Bahlo, J.
    Kluth, S.
    Rhein, C.
    Cramer, P.
    Gross-Ophoff, C.
    Langerbeins, P.
    Fink, A. -M.
    Eichhorst, B.
    Kreuzer, K. -A.
    Tausch, E.
    Stilgenbauer, S.
    Boettcher, S.
    Doehner, H.
    Kneba, M.
    Hallek, M.
    Wendtner, C. -M.
    Bergmann, M.
    Fischer, K.
    Oncology Research and Treatment, 2015, 38 : 92 - 92
  • [50] EFFICACY AND SAFETY OF BENDAMUSTINE IN COMBINATION WITH RITUXIMAB FOR ELDERLY PATIENTS WITH PREVIOUSLY UNTREATED B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA. AN ITALIAN RETROSPECTIVE MULTICENTER STUDY
    Laurenti, L.
    Autore, F.
    Innocenti, I.
    Vannata, B.
    Cantonetti, M.
    Del Principe, M. I.
    Mauro, F. R.
    Borza, P. Anticoli
    Bongarzoni, V.
    Ciolli, S.
    Boncompagni, R.
    Sciume, M.
    Vincenti, D.
    Ghio, F.
    Cecconi, N.
    Pitini, V.
    Mondello, P.
    Cariccio, M. R. Lanza
    Gozzetti, A.
    D'Arena, G.
    Murru, R.
    Piccirillo, N.
    Petrini, M.
    Cortelezzi, A.
    Del Poeta, G.
    Foa, R.
    Sica, S.
    HAEMATOLOGICA, 2014, 99 : 324 - 325
12345